var data={"title":"Hepatitis B immune globulin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hepatitis B immune globulin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6310?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hepatitis-b-immune-globulin-drug-information\" class=\"drug drug_general\">see &quot;Hepatitis B immune globulin: Drug information&quot;</a> and <a href=\"topic.htm?path=hepatitis-b-immune-globulin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hepatitis B immune globulin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178933\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>HepaGam B;</li>\n      <li>HyperHEP B S/D;</li>\n      <li>Nabi-HB</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178934\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>HepaGam B;</li>\n      <li>HyperHEP B S/D</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2649544\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Immune Globulin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442598\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Perinatal exposure, prophylaxis</b> (CDC, 2005): <b>Note:</b> HBIG may be administered at the same time (but at a different site) or up to 1 month preceding hepatitis B vaccination without impairing the active immune response:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neonates born to  HBsAg-positive mothers:</i> IM: 0.5 mL as soon after birth as possible (within 12 hours; efficacy decreases significantly if treatment is delayed &gt;48 hours); hepatitis B vaccine series to begin at the same time; if this series is delayed for as long as 3 months, the HBIG dose may be repeated (Saari, 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neonates born to mothers with unknown HBsAg status at birth:</i> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Birth weight &lt;2 kg: 0.5 mL within 12 hours of birth (along with hepatitis B vaccine) if unable to determine maternal HBsAg status within that time</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Birth weight &ge;2 kg: 0.5 mL within 7 days of birth while awaiting maternal HBsAg results; if mother is determined to be HBsAg positive, administer dose as soon as possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2649554\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=hepatitis-b-immune-globulin-drug-information\" class=\"drug drug_general\">see &quot;Hepatitis B immune globulin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> For exposure prophylaxis, HBIG may be administered at the same time (but at a different site) or up to 1 month preceding hepatitis B vaccination without impairing the active immune response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Perinatal exposure, prophylaxis</b> (CDC, 2005): <i>Infants born to HBsAg-positive mothers:</i> IM: 0.5 mL as a repeat of birth dose if the hepatitis B vaccination series is delayed for as long as 3 months (hepatitis B vaccine should also be administered at the same time/different site)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postexposure, prophylaxis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;12 months: IM: 0.5 mL as soon as possible after exposure (eg, mother or primary caregiver with acute HBV infection); initiate hepatitis B vaccine series </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 months and Adolescents: IM: 0.06 mL/kg as soon as possible after exposure (ie, within 24 hours of needlestick, ocular, or mucosal exposure or within 14 days of sexual exposure); repeat at 28-30 days after exposure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postexposure, prophylaxis:</b> IM: 0.06 mL/kg as soon as possible after exposure (ie, within 24 hours of needlestick, ocular, or mucosal exposure or within 14 days of sexual exposure); repeat at 28-30 days after exposure </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of hepatitis B recurrence in liver transplant patients:</b> IV: HepaGam B&trade;: 20,000 units/dose according to the following schedule:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Anhepatic phase (initial dose): One dose given with the liver transplant</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Week 1 postop: One dose daily for 7 days (days 1-7)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weeks 2-12 postop: One dose every 2 weeks starting on day 14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Month 4 onward: One dose monthly starting on month 4</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dose adjustment:  Adjust dose to reach anti-HB<sub>s</sub> levels of 500 units/L within the first week after transplantation. In patients with surgical bleeding, abdominal fluid drainage &gt;500 mL or those undergoing plasmapheresis, administer 10,000 units/dose every 6 hours until target anti-HBs levels are reached.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosing adjustments provided in the manufacturer labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178920\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HepaGam B:  (1 mL, 5 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HyperHEP B S/D:  (0.5 mL, 1 mL, 5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nabi-HB:  (1 mL, 5 mL) [thimerosal free]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178907\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2649555\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Inject only in the anterolateral aspects of the upper thigh or the deltoid muscle; multiple injections may be necessary when the dosage is a large volume (postexposure prophylaxis). Do not administer hepatitis vaccine and HBIG in same syringe (vaccine will be neutralized); hepatitis vaccine may be administered at the same time at a separate site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HepaGam B: Administer at 2 mL/minute. Decrease infusion to &lt;1 mL/minute for patient discomfort or infusion-related adverse events. Actual volume of dosage is dependent upon potency labeled on each individual vial. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nabi-HB: Although not FDA approved for this purpose, Nabi-HB&reg; has been administered intravenously in hepatitis B-positive liver transplant adult patients (Dickson 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178932\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Refrigerate at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Do not shake vial; avoid foaming.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HepaGamB; Nabi-HB: Use within 6 hours of entering vial.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HyperHEP B S/D: May be exposed to room temperature for a cumulative 7 days (Cohen 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2649545\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: HepaGam  B, HyperHEP B S/D, Nabi-HB: Provide prophylactic postexposure passive immunity to hepatitis B following perinatal exposure of infants born to HBsAg-positive mothers (FDA approved in neonates and infants); provide prophylactic postexposure passive immunity to hepatitis B following acute exposure to blood containing hepatitis B surface antigen (HBsAg), sexual exposure to HBsAg-positive persons, or household exposure to persons with acute HBV infection (FDA approved in infants, children, and adults) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: HepaGam B: Prevention of hepatitis B virus recurrence after liver transplantation in HBsAg-positive transplant patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Hepatitis B immune globulin is not indicated for treatment of active hepatitis B infection and is ineffective in the treatment of chronic active hepatitis B infection. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6052749\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">HBIG may be confused with BabyBIG</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bayhep-B [Philippines, Turkey] may be confused with Bayrab which is a brand name for rabies immune globulin [Philippines, Turkey]; Bayrho-D which is brand name for Rh<sub>o</sub>D immune globulin [Israel, Turkey] </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178949\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Reported with postexposure prophylaxis. Adverse events reported in liver transplant patients included tremor and hypotension, were associated with a single infusion during the first week of treatment, and did not recur with additional infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Cardiovascular: Hypotension </p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Central nervous system: Headache, malaise </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Ecchymoses, erythema </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Change in WBC count </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased liver enzymes, increased serum alkaline phosphatase </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Joint stiffness, myalgia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylactic reaction (rare), angioedema, hypersensitivity, increased serum lipase, increased serum transaminases, sinus tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178926\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HepaGam B: Anaphylactic or severe systemic reaction to human globulin preparations; IgA deficiency; postexposure prophylaxis in patients with severe thrombocytopenia or other coagulation disorders which would contraindicate IM injections (administer only if benefit outweighs the risk)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HyperHEP B S/D: No contraindications listed in manufacturer's labeling</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabi-HB: Anaphylactic or severe systemic reaction to human globulin preparations</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178911\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1 mg/mL) should be available. Use with caution in patients with isolated immunoglobulin A deficiency or a history of systemic hypersensitivity to human immunoglobulins.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: When administered IV, do not exceed recommended infusion rates; may increase risk of adverse events. Patients should be monitored for adverse events during and after the infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic events: Thrombotic events have been reported with administration of intravenous immune globulin; use with caution in patients of advanced age, with a history of atherosclerosis or cardiovascular and/or thrombotic risk factors, patients with impaired cardiac output, coagulation disorders, prolonged immobilization, or patients with known/suspected hyperviscosity. Consider a baseline assessment of blood viscosity in patients at risk for hyperviscosity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with thrombocytopenia or coagulation disorders; IM injections may be contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Maltose: Some products may contain maltose, which may result in falsely-elevated blood glucose readings.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299441\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178915\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13229&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Consult full interaction monograph for dose interval recommendations.  This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions.<b> Exceptions: </b>Influenza Virus Vaccine (Live/Attenuated); Rotavirus Vaccine; Yellow Fever Vaccine; Zoster Vaccine (Live/Attenuated).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178917\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2530309\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Use of HBIG is not contraindicated in pregnant women and may be used for postexposure prophylaxis when indicated (CDC 2001). In addition, use of HBIG has been evaluated to reduce maternal to fetal transmission of hepatis B virus during pregnancy (ACOG 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5203731\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver transplant patients: anti-HB levels; infusion-related adverse events</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178910\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Hepatitis B immune globulin (HBIG) is a nonpyrogenic sterile solution containing immunoglobulin G (IgG) specific to hepatitis B surface antigen (HBsAg). HBIG differs from immune globulin in the amount of anti-HBs. Immune globulin is prepared from plasma that is not preselected for anti-HBs content. HBIG is prepared from plasma preselected for high titer anti-HBs. In the US, HBIG has an anti-HBs high titer &gt;1:100,000 by IRA.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178925\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Postexposure prophylaxis: 3 to 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: IM: Slow</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life: 17 to 25 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 7 to 15 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM: 2 to 10 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178928\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bayhep (PK);</li>\n      <li>Euvax-B (KR);</li>\n      <li>Fovepta (VN);</li>\n      <li>Hebagam IM (ZA);</li>\n      <li>Hep-B Gammagee (AE);</li>\n      <li>HepaBig (EG);</li>\n      <li>Hepabig (IN, KR, MY, PH);</li>\n      <li>Hepacaf (BE);</li>\n      <li>Hepagam B (IL);</li>\n      <li>Hepatect (AT, CH, CO, DE, EE, ES, HN, IE, NO, PL, PT, QA, TR, TW);</li>\n      <li>Hepatect CP (VN);</li>\n      <li>Hepatitis B Immunoglobulin-VF (AU);</li>\n      <li>HepBQuin (IN, NL);</li>\n      <li>Hepuman Berna (PE);</li>\n      <li>Hyperhep (QA);</li>\n      <li>HyperHEP B (HK, IL, NZ, TW);</li>\n      <li>Igantibe (ID);</li>\n      <li>IMMUNOHBs (TH);</li>\n      <li>IVheBex (FR, GR);</li>\n      <li>NEOHepatect (CZ);</li>\n      <li>Niuliva (SG);</li>\n      <li>VENBIG (DK, TH);</li>\n      <li>Zutectra (GB, IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, ACOG Practice Bulletin No. 86: &ldquo;Viral Hepatitis in Pregnancy,&rdquo; <i>Obstet Gynecol</i>, 2007, 110(4):941-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/17906043/pubmed\" target=\"_blank\" id=\"17906043\">17906043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part I: Immunization of Infants, Children, and Adolescents,&rdquo; <i>MMWR Recomm Rep</i>, 2005, 54(RR-16):1-31.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), U.S. Public Health Service, &quot;Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis,&quot; <i>MMWR Recomm Rep</i>, 2001, 50(RR-11):1-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/11442229/pubmed\" target=\"_blank\" id=\"11442229\">11442229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dickson RC, Terrault NA, Ishitani M, et al, &ldquo;Protective Antibody Levels and Dose Requirements for IV 5% Nabi Hepatitis B Immune Globulin Combined With Lamivudine in Liver Transplantation for Hepatitis B-Induced End Stage Liver Disease,&rdquo; <i>Liver Transpl</i>, 2006,  12(1):124-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/16382463/pubmed\" target=\"_blank\" id=\"16382463\">16382463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saari TN and American Academy of Pediatrics Committee on Infectious Diseases, &quot;Immunization of Preterm and Low Birth Weight Infants. American Academy of Pediatrics Committee on Infectious Diseases,&quot; <i>Pediatrics</i>, 2003, 112(1 Pt 1):193-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/12837889/pubmed\" target=\"_blank\" id=\"12837889\">12837889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13229 Version 113.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F178933\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F178934\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F2649544\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442598\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F2649554\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F178920\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F178907\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2649555\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F178932\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2649545\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6052749\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F178949\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F178926\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F178911\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299441\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F178915\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F178917\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2530309\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5203731\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F178910\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F178925\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F178928\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13229|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hepatitis-b-immune-globulin-drug-information\" class=\"drug drug_general\">Hepatitis B immune globulin: Drug information</a></li><li><a href=\"topic.htm?path=hepatitis-b-immune-globulin-patient-drug-information\" class=\"drug drug_patient\">Hepatitis B immune globulin: Patient drug information</a></li></ul></div></div>","javascript":null}